Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: RainDance, Thermo Fisher Scientific, and Celera

NEW YORK (GenomeWeb News) – RainDance Technologies said this week that it has made the first commercial shipment of its RDT 1000 and Sequence Enrichment Solution. The Lexington, Mass.-based firm said that it had shipped the RDT 1000, consumables kits, and custom PCR prime libraries to the Ontario Institute for cancer Research, which will use the products in its discovery and validation of DNA sequence variants associated with cancers.


Thermo Fisher Scientific announced that the University of Middlesex in Hendon, UK, is using its Verso cDNA Synthesis Kit and Absolute Blue QPCR Master Mix in its cancer biomarker research projects.


Celera presented a poster at this week's American College of Medical Genetics meeting in Tampa, Fla., on its prototype Fragile X screening assay. According to the firm, and collaborators from the University of Utah and ARUP Laboratories, the assay "was found to detect expanded alleles in all pre-mutation and full mutation patients with 100 percent sensitivity in both genders, in addition to identifying all non-expanded alleles in patients with 100 percent specificity."


In Brief This Week is a new Friday column containing news items that our readers may have missed during the week.

Filed under

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.